Jun 15, 2020
Cardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AML
Jun 10, 2020
Ryvu Therapeutics Reports First Quarter 2020 Financial Results
May 19, 2020
Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States
May 14, 2020
Ryvu Therapeutics Announces Availability of Abstracts Regarding Phase 1/2 Study of SEL120 and SEL24/MEN1703 Accepted for Presentation at 25th EHA Congress
May 14, 2020
25th EHA Congress: Menarini Ricerche Discloses First Results From the Clinical Study on SEL24/MEN1703
Mar 28, 2020
Ryvu Therapeutics Receives Orphan Drug Designation From FDA for SEL120 to Treat Acute Myeloid Leukemia
Jan 14, 2020
Health Canada Approves Astellas' XOSPATA® (gilteritinib) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Dec 09, 2019
61st ASH Congress 2019: Menarini Ricerche Presents the Latest Updates About the First In Human Clinical Trial of SEL24/MEN1703
Dec 04, 2019
Trovagene Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in Acute Myeloid Leukemia (AML)
Nov 11, 2019
NuProbe Launches Ultrasensitive Sanger Assays for Oncology Therapy Selection and Recurrence Monitoring
Nov 06, 2019
Trovagene Announces Data from Acute Myeloid Leukemia (AML) Phase 1b/2 Trial of Onvansertib Chosen for Oral Presentation at ASH 2019 Annual Meeting
Nov 05, 2019
Ryvu Therapeutics to Present at BIO-Europe 2019
Oct 30, 2019
European Commission Approves Astellas' XOSPATA(TM) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using Invivoscribe's LeukoStrat® CDx FLT3 Mutation Assay
Oct 29, 2019
Clinical Trials in Gene Sequencing Reveal Novel Mutations Aiding in New Treatments for Acute Myeloid Leukemia
Oct 25, 2019
European Commission Approves Astellas' XOSPATA(TM) (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Oct 21, 2019
Acute Myeloid Leukemia Market Expected to Reach $2.2 Billion Dollars By 2025
Sep 28, 2019
Tolero Pharmaceuticals Presents Preliminary Findings from Phase 1 Study Evaluating Investigational Agent TP-0903 in Patients with Advanced Solid Tumors at ESMO 2019
Sep 20, 2019
Astellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Sep 19, 2019
Trovagene Announces Successful Completion of Phase 1b Trial of Onvansertib in Acute Myeloid Leukemia (AML) and Initiation of Patient Enrollment in Phase 2
Sep 06, 2019
Selvita Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome